Novartis has secured the exclusive global rights to use Regenerex's stem cell technology, which has potential applications in oncology, transplantation and metabolic disorders. The firms will collaborate on research as part of the deal. A study published last year showed the stem cell technology allowed five of eight kidney transplant recipients to stop taking about a dozen daily anti-rejection pills.

Full Story:

Related Summaries